Supporting early clinical development with the right material strategy

Human Absorption, Metabolism and Excretion (hAME) clinical pharmacology studies rely on well-defined, fit-for-purpose clinical trial materials. Early Chemistry, Manufacturing and Controls (CMC) decisions directly influence data quality, timelines and regulatory alignment in these studies. A proactive CMC strategy helps ensure that investigational products used in hAME CPS studies are appropriate for their intended use, analytically understood and aligned with global regulatory expectations.